drugset / Trial / NCT05263739
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Phase 1
Withdrawn
Shanghai Escugen Biotechnology Co., Ltd
Escugen (Australia) Biotechnology Pty Ltd · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and preliminary efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult subjects with B lymphoid malignancies.
Timeline
- Start
- 2025-12
- Primary completion
- 2026-08
- Completion
- 2026-12
Outcome
Outcome not reported
Stopped (Business): “Due to the company's development strategy adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ESG206 | Monoclonal antibody | — | Intravenous |